These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31131924)

  • 1. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
    Sadik CD; Thieme M; Zillikens D; Terheyden P
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
    [No Abstract]   [Full Text] [Related]  

  • 2. Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum.
    Salvia G; Bevilacqua M; Manzo Margiotta F; Michelucci A; Granieri G; Fidanzi C; Dini V; Romanelli M; Mazzatenta C
    Australas J Dermatol; 2024 Jun; 65(4):e111-e113. PubMed ID: 38597123
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction.
    Wollina U; Schönlebe J; Fürll C
    Dermatol Ther; 2020 Jan; 33(1):e13161. PubMed ID: 31705566
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 5. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
    Machado Á; Abreu M; Torres T
    Eur J Dermatol; 2020 Dec; 30(6):740-741. PubMed ID: 33237033
    [No Abstract]   [Full Text] [Related]  

  • 7. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab.
    Vestita M; Guida S; Mazzoccoli S; Loconsole F; Foti C
    Eur J Dermatol; 2015; 25(3):272-3. PubMed ID: 25786592
    [No Abstract]   [Full Text] [Related]  

  • 9. Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab.
    Vilaça S; Torres T; Selores M
    Eur J Dermatol; 2013; 23(6):897-8. PubMed ID: 24192318
    [No Abstract]   [Full Text] [Related]  

  • 10. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 12. Local injection of micro-dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment.
    Zhou C; Chen D; Diao Z; Wang Y; Hou Y; Yin Z
    Australas J Dermatol; 2024 May; 65(3):e75-e76. PubMed ID: 38439213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palmoplantar psoriasis or palmoplantar keratoderma? Successful treatment with brodalumab.
    Buononato D; Giorgio CMR; Carraturo E; Pagliuca F; Argenziano G; Balato A
    Int J Dermatol; 2024 Sep; 63(9):1272-1273. PubMed ID: 38600612
    [No Abstract]   [Full Text] [Related]  

  • 14. Secukinumab-induced pompholyx in a psoriasis patient.
    Eichhoff G
    Dermatol Online J; 2020 Apr; 26(4):. PubMed ID: 32621689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.
    Ferrières L; Konstantinou MP; Bulai Livideanu C; Hegazy S; Tauber M; Amelot F; Paul C
    Clin Exp Dermatol; 2019 Oct; 44(7):e230-e234. PubMed ID: 31055846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Lee JE; Wang J; Florian J; Wang YM; Kettl D; Marcus K; Woitach A
    Clin Pharmacol Ther; 2019 Jul; 106(1):78-80. PubMed ID: 31188469
    [No Abstract]   [Full Text] [Related]  

  • 17. First cases of ustekinumab-induced spondylodiscitis and sacroiliitis in patients with psoriasis successfully treated with pentoxyfilline.
    Skayem C; Ayoub N
    Dermatol Ther; 2020 Jul; 33(4):e13728. PubMed ID: 32475020
    [No Abstract]   [Full Text] [Related]  

  • 18. Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Brodalumab.
    Gambardella A; Licata G; De Rosa A; Pagliuca F; Calabrese G; Alfano R; Argenziano G
    Dermatitis; 2021 Oct; 32(1S):e86-e88. PubMed ID: 33208631
    [No Abstract]   [Full Text] [Related]  

  • 19. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 20. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.
    Benzaquen M; Monnier J; Beaussault Y; Rouby F; Berbis P
    Australas J Dermatol; 2017 Nov; 58(4):e270-e271. PubMed ID: 28660635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.